Conséquences économiques de l'erlotinib dans le traitement des cancers bronchopulmonaires non à petites cellules

The treatments lasted a similar length in the second- line setting (respectively 94,5±67,5 and 105±79,4 days for the IV and erlotinib cohorts) but was significantly longer in the erlotinib cohort during third-line therapy (76.6±96.5 versus and 114.4±74.5 days, p<0.008). In the erlotinib cohort, there were more women (p=0.023), a higher rate of adenocarcinoma (p = 0.0043), a similar rate of conventional hospitalization, but less daycare clinics (p<0.001). The erlotinib cohort received significantly less antiemetic treatment (p<0.0001), erythropoietin stimulating agents (p<0.005) and G-CSF (p<0.001). Monthly management costs per patient in the IV and erlotinib cohorts were respectively 3126 ±1904 and 2750±1450 euros during second-line treatment, and 3026±1029 and 2823±1490 euros during third-line treatment (no significant difference). These results must be validated by prospective observational studies focusing on quality of life and the time spent in hospital.